Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging–targeted Biopsy
Giorgio Gandaglia(Vita-Salute San Raffaele University), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Giancarlo Marra(Royal Free London NHS Foundation Trust), Paolo Gontero(Fondazione Ricerca Molinette), Luca Afferi(Universitat Autònoma de Barcelona), Alberto Martini(The University of Texas MD Anderson Cancer Center), Jean‐Baptiste Beauval, M. Roumiguié(Institut universitaire du cancer de Toulouse Oncopole), Arnas Rakauskas(University of Lausanne), Massimo Valério(University Hospital of Geneva), Francesco Montorsi(Vita-Salute San Raffaele University), Armando Stabile(Royal Free London NHS Foundation Trust), Agostino Mattei(Luzerner Kantonsspital), Simone Scuderi(University of Catania), Nicola Fossati(Ospedale regionale di Lugano), Marco Moschini(Vita-Salute San Raffaele University), Bernard Malavaud(Université Toulouse III - Paul Sabatier), Guillaume Ploussard(Yves Rocher (France)), Francesco Barletta(Vita-Salute San Raffaele University)
Cited by 53
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
|European Urology|2020|396
Epidemiology, Screening, and Prevention of Bladder Cancer
|European Urology Oncology|2022|361